• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Emerging Molecular Technologies in Genitourinary Tumors.泌尿生殖系统肿瘤中的新兴分子技术
Front Oncol. 2018 Oct 30;8:489. doi: 10.3389/fonc.2018.00489. eCollection 2018.
2
Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.泌尿生殖系统肿瘤：分子生物标志物在诊断、预后和预测治疗反应方面的最新进展。
Curr Drug Metab. 2019;20(4):305-312. doi: 10.2174/1389200220666190225124352.
3
Present and future of personalized medicine in adult genitourinary tumors.成人泌尿生殖系统肿瘤个性化医疗的现状与未来
Future Oncol. 2015;11(9):1381-8. doi: 10.2217/fon.15.30.
4
Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.泌尿生殖系统癌症个性化管理的形态学和分子背景：综述
Curr Drug Targets. 2015;16(2):96-102. doi: 10.2174/1389450115666141202113805.
5
Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.高效利用患者来源的类器官作为妇科肿瘤的临床前模型。
Gynecol Oncol. 2019 Jul;154(1):189-198. doi: 10.1016/j.ygyno.2019.05.005. Epub 2019 May 14.
6
Cancer Genetics and Therapeutic Opportunities in Urologic Practice.泌尿外科实践中的癌症遗传学与治疗机遇
Cancers (Basel). 2020 Mar 18;12(3):710. doi: 10.3390/cancers12030710.
7
Editorial: Emerging Biomarkers in Genitourinary Tumors.社论：泌尿生殖系统肿瘤中的新兴生物标志物
Front Oncol. 2019 Apr 26;9:326. doi: 10.3389/fonc.2019.00326. eCollection 2019.
8
Molecular Pathology of the Genitourinary Tract: Prostate and Bladder.泌尿生殖道的分子病理学：前列腺和膀胱
Surg Pathol Clin. 2008 Dec;1(1):211-36. doi: 10.1016/j.path.2008.08.002. Epub 2008 Dec 6.
9
Role of STAT3 pathway in genitourinary tumors.信号转导与转录激活因子3（STAT3）通路在泌尿生殖系统肿瘤中的作用
Future Sci OA. 2015 Nov 1;1(3):FSO15. doi: 10.4155/fso.15.13. eCollection 2015 Nov.
10
Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.双膦酸盐类药物在前列腺癌和其他泌尿生殖系统癌症中的抗癌活性。
Anticancer Agents Med Chem. 2012 Feb;12(2):129-36. doi: 10.2174/187152012799014995.

引用本文的文献

1
A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.一瞥最常见的泌尿生殖系统癌症中新兴的诊断生物标志物。
Saudi J Biol Sci. 2022 Apr;29(4):2072-2084. doi: 10.1016/j.sjbs.2022.01.017. Epub 2022 Jan 15.

本文引用的文献

1
Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.根据临床和病理特征，局限性前列腺癌中 DNA 修复基因突变的流行情况：与 Gleason 评分和肿瘤分期的关系。
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59-65. doi: 10.1038/s41391-018-0086-1. Epub 2018 Aug 31.
2
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.DNA 修复基因改变与转移性去势抵抗性前列腺癌患者对 PARP 抑制剂的反应。
J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020.
3
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.前列腺癌阿比特龙和恩杂鲁胺耐药患者来源模型揭示了对核糖体导向治疗的敏感性。
Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.
4
Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer.探索小细胞外囊泡用于前列腺癌的精准医学
Front Oncol. 2018 Jun 13;8:221. doi: 10.3389/fonc.2018.00221. eCollection 2018.
5
Patient derived organoids to model rare prostate cancer phenotypes.基于患者来源的类器官模型来研究罕见前列腺癌表型。
Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.
6
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer.泌尿生殖系统肿瘤侵袭性的生物标志物，重点是肾、膀胱和前列腺癌。
Expert Rev Mol Diagn. 2018 Jul;18(7):645-655. doi: 10.1080/14737159.2018.1490179. Epub 2018 Jun 29.
7
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.膀胱癌患者来源类器官模型中的肿瘤进化和药物反应。
Cell. 2018 Apr 5;173(2):515-528.e17. doi: 10.1016/j.cell.2018.03.017.
8
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.种系 DNA 修复基因突变与一线接受阿比特龙和恩杂鲁胺治疗的转移性去势抵抗性前列腺癌男性的结局
Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.
9
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.原发性和转移性膀胱癌中 PD-L1 表达的一致性研究：四种常用抗体和 RNA 表达的比较。
Mod Pathol. 2018 Apr;31(4):623-632. doi: 10.1038/modpathol.2017.188. Epub 2017 Dec 22.
10
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.遗传性前列腺癌风险的基因检测作用：2017 年费城前列腺癌共识会议。
J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.

Emerging Molecular Technologies in Genitourinary Tumors.

作者信息

Giunchi Francesca, Cimadamore Alessia, Fiorentino Michelangelo

机构信息

Laboratory of Oncologic Molecular Pathology, S. Orsola-Malpighi Teaching Hospital University of Bologna, Bologna, Italy.

Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.

出版信息

Front Oncol. 2018 Oct 30;8:489. doi: 10.3389/fonc.2018.00489. eCollection 2018.

DOI:10.3389/fonc.2018.00489
PMID:30425967
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6218401/
Abstract
摘要